|
1
|
Cooper DS, Doherty GM, Haugen BR, Kloos
RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI and
Tuttle RM: American Thyroid Association Guidelines Taskforce:
Management guidelines for patients with thyroid nodules and
differentiated thyroid cancer. Thyroid. 16:109–142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
American Thyroid Association (ATA)
Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer, ; Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL,
Mandel SJ, Mazzaferri EL, McIver B, Pacini F, et al: Revised
American thyroid association management guidelines for patients
with thyroid nodules and differentiated thyroid cancer. Thyroid.
19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan GH and Gharib H: Thyroid
incidentalomas: Management approaches to nonpalpable nodules
discovered incidentally on thyroid imaging. Ann Intern Med.
126:226–231. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Singer PA, Cooper DS, Daniels GH, Ladenson
PW, Greenspan FS, Levy EG, Braverman LE, Clark OH, McDougall IR,
Ain KV and Dorfman SG: Treatment guidelines for patients with
thyroid nodules and well-differentiated thyroid cancer. American
thyroid association. Arch Intern Med. 156:2165–2172. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ito Y, Kudo T, Kobayashi K, Miya A,
Ichihara K and Miyauchi A: Prognostic factors for recurrence of
papillary thyroid carcinoma in the lymph nodes, lung and bone:
Analysis of 5,768 patients with average 10-year follow-up. World J
Surg. 36:1274–1278. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang IC, Chou FF, Liu RT, Tung SC, Chen
JF, Kuo MC, Hsieh CJ and Wang PW: Long-term outcomes of distant
metastasis from differentiated thyroid carcinoma. Clin Endocrinol
(Oxf). 76:439–447. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Konturek A, Barczyński M, Nowak W and
Richter P: Prognostic factors in differentiated thyroid cancer-a
20-year surgical outcome study. Langenbecks Arch Surg. 397:809–815.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheung CC, Carydis B, Ezzat S, Bedard YC
and Asa SL: Analysis of ret/PTC gene rearrangements refines the
fine needle aspiration diagnosis of thyroid cancer. J Clin
Endocrinol Metab. 86:2187–2190. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pizzolanti G, Russo L, Richiusa P, Bronte
V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M,
et al: Fine-needle aspiration molecular analysis for the diagnosis
of papillary thyroid carcinoma through BRAF V600E mutation and
RET/PTC rearrangement. Thyroid. 17:1109–1115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Faggiano A, Caillou B, Lacroix L, Talbot
M, Filetti S, Bidart JM and Schlumberger M: Functional
characterization of human thyroid tissue with immunohistochemistry.
Thyroid. 17:203–211. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Beatty PL, Cascio S and Lutz E: Tumor
immunology: Basic and clinical advances. Cancer Res. 71:4338–4343.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Boon T and Old LJ: Cancer tumor antigens.
Curr Opin Immunol. 9:681–683. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ
and Chen YT: Cancer/testis antigens: An expanding family of targets
for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Scanlan MJ, Simpson AJ and Old LJ: The
cancer/testis genes: Review, standardization, and commentary.
Cancer Immun. 4:12004.PubMed/NCBI
|
|
15
|
Simpson AJ, Caballero OL, Jungbluth A,
Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and
cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bodey B: Cancer-testis antigens: Promising
targets for antigen directed antineoplastic immunotherapy. Expert
Opin Biol Ther. 2:577–584. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fratta E, Coral S, Covre A, Parisi G,
Colizzi F, Danielli R, Nicolay HJ, Sigalotti L and Maio M: The
biology of cancer testis antigens: Putative function, regulation
and therapeutic potential. Mol Oncol. 5:164–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jungbluth AA, Stockert E, Chen YT, Kolb D,
Iversen K, Coplan K, Williamson B, Altorki N, Busam KJ and Old LJ:
Monoclonal antibody MA454 reveals a heterogeneous expression
pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung
tumours. Br J Cancer. 83:493–497. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Landry C, Brasseur F, Spagnoli GC, Marbaix
E, Boon T, Coulie P and Godelaine D: Monoclonal antibody 57B stains
tumor tissues that express gene MAGE-A4. Int J Cancer. 86:835–841.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rimoldi D, Salvi S, Schultz-Thater E,
Spagnoli GC and Cerottini JC: Anti-MAGE-3 antibody 57B and
anti-MAGE-1 antibody 6C1 can be used to study different proteins of
the MAGE-A family. Int J Cancer. 86:749–751. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Milkovic M, Sarcevic B and Glavan E:
Expression of MAGE tumor-associated antigen in thyroid carcinomas.
Endocr Pathol. 17:45–52. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Inaoka RJ, Jungbluth AA, Baiocchi OC,
Assis MC, Hanson NC, Frosina D, Tassello J, Bortoluzzo AB, Alves AC
and Colleoni GW: An overview of cancer/testis antigens expression
in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and
MAGE-C1 as the most frequently expressed antigens in a set of
Brazilian cHL patients. BMC Cancer. 11:4162011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jungbluth AA, Busam KJ, Kolb D, Iversen K,
Coplan K, Chen YT, Spagnoli GC and Old LJ: Expression of
MAGE-antigens in normal tissues and cancer. Int J Cancer.
85:460–465. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Krishnadas DK, Shusterman S, Bai F, Diller
L, Sullivan JE, Cheerva AC, George RE and Lucas KG: A phase I trial
combining decitabine/dendritic cell vaccine targeting MAGE-A1,
MAGE-A3 and NY-ESO-1 for children with relapsed or
therapy-refractory neuroblastoma and sarcoma. Cancer Immunol
Immunother. 64:1251–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jungbluth AA, Chen YT, Busam KJ, Coplan K,
Kolb D, Iversen K, Williamson B, Van Landeghem FK, Stockert E and
Old LJ: CT7 (MAGE-C1) antigen expression in normal and neoplastic
tissues. Int J Cancer. 99:839–845. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Curioni-Fontecedro A, Knights AJ, Tinguely
M, Nuber N, Schneider C, Thomson CW, von Boehmer L, Bossart W,
Pahlich S, Gehring H, et al: MAGE-C1/CT7 is the dominant
cancer-testis antigen targeted by humoral immune responses in
patients with multiple myeloma. Leukemia. 22:1646–1648. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Curioni-Fontecedro A, Nuber N,
Mihic-Probst D, Seifert B, Soldini D, Dummer R, Knuth A, van den
Broek M and Moch H: Expression of MAGE-C1/CT7 and MAGE-C2/CT10
predicts lymph node metastasis in melanoma patients. PLoS One.
6:e214182011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jungbluth AA, Chen YT, Stockert E, Busam
KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N and Old
LJ: Immunohistochemical analysis of NY-ESO-1 antigen expression in
normal and malignant human tissues. Int J Cancer. 92:856–860. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gjerstorff MF, Pøhl M, Olsen KE and Ditzel
HJ: Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen
expression in early stage non-small cell lung carcinoma. BMC
Cancer. 13:4662013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ademuyiwa FO, Bshara W, Attwood K,
Morrison C, Edge SB, Karpf AR, James SA, Ambrosone CB, O'Connor TL,
Levine EG, et al: NY-ESO-1 cancer testis antigen demonstrates high
immunogenicity in triple negative breast cancer. PLoS One.
7:e387832012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Robbins PF, Morgan RA, Feldman SA, Yang
JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ,
Mackall CL, et al: Tumor regression in patients with metastatic
synovial cell sarcoma and melanoma using genetically engineered
lymphocytes reactive with NY-ESO-1. J Clin Oncol. 29:917–924. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cilensek ZM, Yehiely F, Kular RK and Deiss
LP: A member of the GAGE family of tumor antigens is an
anti-apoptotic gene that confers resistance to Fas/CD95/APO-1,
interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther.
1:380–387. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gnjatic S, Nishikawa H, Jungbluth AA, Güre
AO, Ritter G, Jäger E, Knuth A, Chen YT and Old LJ: NY-ESO-1:
Review of an immunogenic tumor antigen. Adv Cancer Res. 95:1–30.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Curigliano G, Viale G, Ghioni M, Jungbluth
AA, Bagnardi V, Spagnoli GC, Neville AM, Nolè F, Rotmensz N and
Goldhirsch A: Cancer-testis antigen expression in triple-negative
breast cancer. Ann Oncol. 22:98–103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhuang R, Zhu Y, Fang L, Liu XS, Tian Y,
Chen LH, Ouyang WM, Xu XG, Jian JL, Güre AO, et al: Generation of
monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2.
Cancer Immun. 6:72006.PubMed/NCBI
|
|
36
|
Sharma P, Shen Y, Wen S, Bajorin DF,
Reuter VE, Old LJ and Jungbluth AA: Cancer-testis antigens:
Expression and correlation with survival in human urothelial
carcinoma. Clin Cancer Res. 12:5442–5447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jungbluth AA, Silva WA Jr, Iversen K,
Frosina D, Zaidi B, Coplan K, Eastlake-Wade SK, Castelli SB,
Spagnoli GC, Old LJ and Vogel M: Expression of cancer-testis (CT)
antigens in placenta. Cancer Immun. 7:152007.PubMed/NCBI
|
|
38
|
Grigoriadis A, Caballero OL, Hoek KS, da
Silva L, Chen YT, Shin SJ, Jungbluth AA, Miller LD, Clouston D,
Cebon J, et al: CT-X antigen expression in human breast cancer.
Proc Natl Acad Sci USA. 106:pp. 13493–13498. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cheng S, Liu W, Mercado M, Ezzat S and Asa
SL: Expression of the melanoma-associated antigen is associated
with progression of human thyroid cancer. Endocr Relat Cancer.
16:455–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Noguchi T, Kato T, Wang L, Maeda Y, Ikeda
H, Sato E, Knuth A, Gnjatic S, Ritter G, Sakaguchi S, et al:
Intracellular tumor-associated antigens represent effective targets
for passive immunotherapy. Cancer Res. 72:1672–1682. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Inaoka RJ, Jungbluth AA, Gnjatic S, Ritter
E, Hanson NC, Frosina D, Tassello J, Etto LY, Bortoluzzo AB, Alves
AC and Colleoni GW: Cancer/testis antigens expression and
autologous serological response in a set of Brazilian non-Hodgkin's
lymphoma patients. Cancer Immunol Immunother. 61:2207–2214. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Melo DH, Mamede RC, Neder L, Saggioro FP,
Figueiredo DL, da Silva WA Jr, Jungbluth AA and Zago MA: Expression
of MAGE-A4 and MAGE-C1 tumor-associated antigen in benign and
malignant thyroid diseases. Head Neck. 33:1426–1432. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sigalotti L, Covre A, Nicolay HJ, Coral S
and Maio M: Cancer testis antigens and melanoma stem cells: New
promises for therapeutic intervention. Cancer Immunol Immunother.
59:487–488. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Saldanha-Araujo F, Haddad R, Zanette DL,
De Araujo AG, Orellana MD, Covas DT, Zago MA and Panepucci RA:
Cancer/Testis antigen expression on mesenchymal stem cells isolated
from different tissues. Anticancer Res. 30:5023–5017.
2010.PubMed/NCBI
|
|
45
|
Chen YT, Ross DS, Chiu R, Zhou XK, Chen
YY, Lee P, Hoda SA, Simpson AJ, Old LJ, Caballero O and Neville AM:
Multiple cancer/testis antigens are preferentially expressed in
hormone-receptor negative and high-grade breast cancers. PLoS One.
6:e178762011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gunda V, Frederick DT, Bernasconi MJ,
Wargo JA and Parangi S: A potential role for immunotherapy in
thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
Thyroid. 24:1241–1250. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tinguely M, Jenni B, Knights A, Lopes B,
Korol D, Rousson V, Fontecedro A Curioni, Cogliatti SB, Bittermann
AG, Schmid U, et al: MAGE-C1/CT-7 expression in plasma cell
myeloma: Sub-cellular localization impacts on clinical outcome.
Cancer Sci. 99:720–725. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Barrow C, Browning J, MacGregor D, Davis
ID, Sturrock S, Jungbluth AA and Cebon J: Tumor antigen expression
in melanoma varies according to antigen and stage. Clin Cancer Res.
12:764–771. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Groeper C, Gambazzi F, Zajac P, Bubendorf
L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M and Spagnoli GC:
Cancer/testis antigen expression and specific cytotoxic T
lymphocyte responses in non small cell lung cancer. Int J Cancer.
120:337–343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Atanackovic D, Arfsten J, Cao Y, Gnjatic
S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C,
Dierlamm J, et al: Cancer-testis antigens are commonly expressed in
multiple myeloma and induce systemic immunity following allogeneic
stem cell transplantation. Blood. 109:1103–1112. 2007. View Article : Google Scholar : PubMed/NCBI
|
